Table 1.
Patient characteristics and treatments.
| Characteristics | All (%) (n=16) |
|---|---|
| Age (year) | |
| Median(range) | 51.5(21-74) |
| Gender | |
| Male | 14 (87.5) |
| Female | 2 (12.5) |
| ECOG score | |
| 0 | 1 (6.3) |
| 1 | 10 (62.5) |
| 2 | 5 (31.3) |
| Serum AFP level, ng/mL | |
| <400 | 7 (43.8) |
| ≧400 | 9 (56.3) |
| Child-Pugh class | |
| A | 13 (81.3) |
| B | 3 (18.8) |
| HBV infection | 13 (81.3) |
| Portal vein invasion | 8 (50.0) |
| Extrahepatic spread | 11 (68.8) |
| Duration of PD-1/PDL-1 inhibitors a (day) | |
| Median(range) | 153 (0-488) |
| Course of PD-1/PDL-1 inhibitors | |
| Median(range) | 6.5(1-14) |
| Radiotherapy site | |
| Liver | 8 (50.0) |
| Bone | 5 (31.3) |
| Brain | 1 (6.3) |
| Inferior vena cava tumor thrombus | 1 (6.3) |
| Soft tissue of the lumbar spine | 1 (6.3) |
| Radiotherapy dose (Gray) | |
| Median(range) | 43.5(30-60) |
| Radiotherapy technique | |
| SBRT | 6 (37.5) |
| Hypofractionated radiotherapy | 7 (43.8) |
| Conventional radiotherapy | 3 (18.8) |
| Prior treatment | |
| No | 4 (25.0) |
| Hepatectomy | 6 (37.5) |
| Radiofrequency ablation | 5 (31.3) |
| TACE | 9 (56.3) |
| Targeted agents b | 7 (43.8) |
a
Including camrelizumab (n=5), sintilimab (n=3), tislelizumab (n=2), pembrolizumab (n=1), nivolumab (n=1), toripalimab (n=1), atezolizumab (n=1), sequential therapy (n=2).
b
Including lenvatinib (n=2), sorafenib (n=1), apatinib (n=1), sequential therapy (n=3).
ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein; HBV, hepatitis B virus; SBRT, stereotactic body radiotherapy; TACE, trans-arterial chemo-embolization.